165 related articles for article (PubMed ID: 34986195)
1. Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia.
Ng Ombe H; Simuyandi M; Mwaba J; Luchen CC; Alabi P; Chilyabanyama ON; Mubanga C; Hatyoka LM; Muchimba M; Bosomprah S; Chilengi R; Kwenda G; Chisenga CC
PLoS One; 2022; 17(1):e0262239. PubMed ID: 34986195
[TBL] [Abstract][Full Text] [Related]
2. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
[TBL] [Abstract][Full Text] [Related]
3. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia.
Chisenga CC; Bosomprah S; Chilyabanyama ON; Alabi P; Simuyandi M; Mwaba J; Ng'ombe H; Laban NM; Luchen CC; Chilengi R
BMC Public Health; 2023 Jan; 23(1):152. PubMed ID: 36690955
[TBL] [Abstract][Full Text] [Related]
7. Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia.
Luchen CC; Mwaba J; Ng'ombe H; Alabi PIO; Simuyandi M; Chilyabanyama ON; Hatyoka LM; Mubanga C; Bosomprah S; Chilengi R; Chisenga CC
PLoS One; 2021; 16(12):e0260552. PubMed ID: 34855835
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
[TBL] [Abstract][Full Text] [Related]
10. Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia.
Mwaba J; Chisenga CC; Xiao S; Ng'ombe H; Banda E; Shea P; Mabula-Bwalya C; Mwila-Kazimbaya K; Laban NM; Alabi P; Chirwa-Chobe M; Simuyandi M; Harris J; Iyer AS; Bosomprah S; Scalzo P; Murt KN; Ram M; Kwenda G; Ali M; Sack DA; Chilengi R; Debes AK
Vaccine; 2021 Jul; 39(32):4516-4523. PubMed ID: 34217572
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
12. The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants.
Saha A; Khan A; Salma U; Jahan N; Bhuiyan TR; Chowdhury F; Khan AI; Khanam F; Muruganandham S; Reddy Kandukuri S; Singh Dhingra M; Clemens JD; Cravioto A; Qadri F
Vaccine; 2016 Mar; 34(13):1551-1558. PubMed ID: 26896684
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.
Shah S; Nandy RK; Sethi SS; Chavan B; Pathak S; Dutta S; Rai S; Singh C; Chayal V; Patel C; Kumar NR; Chavan AT; Chawla A; Singh A; Roy AK; Singh N; Baik YO; Lee Y; Park Y; Jeong KH; Ahmed S
Lancet Reg Health Southeast Asia; 2023 Dec; 19():100256. PubMed ID: 38076719
[TBL] [Abstract][Full Text] [Related]
14. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
[TBL] [Abstract][Full Text] [Related]
16. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
17. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States.
McCarty JM; Cassie D; Bedell L; Lock MD; Bennett S
Am J Trop Med Hyg; 2021 Apr; 104(5):1758-1760. PubMed ID: 33819178
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
